New osteoporosis drug could offer cheaper alternative to prolia
NCT ID NCT05345691
First seen Jun 25, 2026 · Last updated Jun 26, 2026 · Updated 1 time
Summary
This phase 3 trial tested whether a biosimilar called Bmab 1000 works as well as the established drug Prolia® for treating osteoporosis in postmenopausal women. 479 women aged 55-79 with osteoporosis received either Bmab 1000 or Prolia® as an injection every 6 months. The study measured changes in bone density and bone turnover markers to see if the two drugs are equivalent.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Bmab 1000 (a biosimilar of denosumab, given as an injection every 6 months)
What this could lead to
If successful, this could provide a more affordable treatment option for osteoporosis, helping to prevent fractures in postmenopausal women.
What could go wrong
This is a biosimilar comparison trial, not a new breakthrough. Even if it works, it may not offer any advantage over the existing drug, and long-term safety data are still limited.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for OSTEOPOROSIS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
PPD Global Ltd, Granta Park, Great Abington,
Cambridge, UK, CB21 6GQ, United Kingdom